Lexaria Bioscience Corp. (NASDAQ: LEXX) Eyes Additional Revenue Opportunities for 2024; Continues to Generate New Data for its DehydraTECH Technology
Lexaria, a global innovator in drug delivery platforms, is projected by Zacks SCR to be valued at $10 a share,…